Less than 10% of individuals eligible to benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it issues its first guidance on the therapies.
With in excess of 1,000,000,000 people worldwide currently obese, it is urging increased and just availability to GLP-1 medication.
Based on estimates, more than two billion could be obese by 2030 without intervention.
"Our new guidelines acknowledges that obesity is a long-term condition that can be addressed with thorough and continuous treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major barriers to universal availability to the injections that can assist patients in reducing considerable weight, notes the body.
Weight-Loss Drug Scarcity
Even in the current most favorable outlook, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of the global need, per the health organization.
The advice encourages nations and manufacturers to widen availability, by strategies including patent sharing.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is set to lapse in several nations in 2026.
How Obesity Injections Work
The injections replicate a body's own hormone to reduce digestion speed, suppress the appetite and enhance satiety so individuals consume fewer calories.
Patients commonly see weight reduction after several weeks of starting on the once-weekly jabs.
Evidence indicates patients may put most of the weight back on within a year of halting the medication, as their normal appetite return.
To be above a healthy weight increases your likelihood for experiencing diseases, including diabetes, heart disease, stroke, and specific cancers.
Obesity concerns individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
